Sourcing, Producing & Recycling Paper Across the U.S.

Amcor announced an investment to establish new thermoforming capabilities for medical packaging in its Sligo, Ireland, healthcare packaging facility. The multi-million-dollar investment will strengthen Amcor’s leadership in the growing industry for sterile packaging, offering customers in Europe and North America another site with comprehensive healthcare solutions. “The additional capabilities in our Sligo site allow us to provide customers with even more differentiated and efficient solutions to meet their healthcare packaging needs,” said Amcor’s Chief Commercial Officer Peter Konieczny. “With our global scale and innovation capabilities, Amcor is uniquely positioned to capture growing demand for both medical and pharmaceutical packaging products globally.”

Third Quarter 2020 Summary: *Reported sales increased 8%, including positive effects of currency translation rates and recent acquisitions, and core sales increased 2% *Strong reported and core growth in our Pharma segment *Core sales growth in the food, personal care and home care markets *Recent acquisitions are performing well *Reported earnings per share totaled $0.95 (an increase of 12% compared to the prior year) *Reported net income totaled $64 million (an increase of 12% compared to the prior year) *Cash flow from operations was $381 million in the first nine months of 2020 (a slight increase over the prior year)

Sales of $1,103 million increased by $82 million or 8% compared to the same period last year, reflecting the consolidation of results from the Greenpac Mill beginning in the second quarter, improved pricing and sales mix in all four of the Corporation's business segments, and additional sales from recovery and recycling activities due to higher recycled fibre pricing. These benefits were partially offset by lower volumes in our North American operations, and the stronger Canadian dollar which resulted in a less favourable CAD/USD exchange rate. Third quarter operating income stood at $51 million , a slight improvement from $50 million last year. This performance reflects the inclusion of Greenpac in the current quarter, price increases mainly in Containerboard, and lower Corporate activities costs related to lower stock-based compensation expense. These were offset by higher raw material costs, and higher production costs in Containerboard and Tissue, due to freight and logistics, and increased use of outside contracting. Specific items recorded in the current period (please refer to the ''Supplemental Information on Non-IFRS Measures'' section for more details) decreased operating income by $2 million . On an adjusted basis, third quarter operating income stood at $53 million , down slightly from $55 million in the prior year period. Click Read More below for additional information.